Cannabis & Athletic Performance: What the Evidence Shows (2026)

The Bottom-Line Verdict Strong evidence

The peer-reviewed performance-science verdict on cannabis is clear and underwhelming. Cannabis (THC) is not ergogenic. It raises resting and submaximal heart rate, modestly bronchodilates, mildly impairs reaction time and coordination, and shortens time-to-exhaustion. CBD — the non-intoxicating cannabinoid removed from the WADA Prohibited List effective January 1, 2018 — shows promising but preliminary evidence for sleep, anxiety, and inflammation, with a documented marketing-vs-evidence gap and a real THC-contamination risk for tested athletes.

The Doping Authority Netherlands has publicly stated that cannabinoids "most likely have a negative impact on athletic performance" — a remarkable finding from a national anti-doping organization, given that WADA's continued in-competition ban is partly justified by a (contested) performance-enhancement rationale.

What THC Does to the Working Athlete

The classic Renaud and Cormier study (Medicine & Science in Sports & Exercise, 1986) had 12 healthy young men cycle to exhaustion 10 minutes after smoking a 1.7%-THC cigarette. Findings: pre-exercise tachycardia (94 → 119 bpm), no change in peak VO2/VCO2/HRmax, but exercise duration was reduced (16.1 → 15.1 min), with modest bronchodilation (FEV1 4.28 → 4.43 L). Earlier work by Steadward and Singh (Medicine and Science in Sports, 1975) and Avakian et al. (Aviation, Space, and Environmental Medicine, 1979) reported similar patterns — heart-rate elevation at submaximal workloads, no ergogenic benefit, and reduced economy.

A more recent Ewell et al. (Sports Medicine, 2023) study of 10 mg ingested THC in habitual users found "neither ergogenic nor ergolytic" effect on cycle ergometry. The Burr & Cheung systematic review for the Gatorade Sports Science Institute (Sports Science Exchange #218, 2021) concluded that no quality evidence supports ergogenic claims for THC. For the deeper dive on dose-response, anaerobic effects, and the bronchodilation question, see THC and athletic performance.

What CBD Plausibly Does — and What It Does Not Moderate evidence

CBD's pharmacology is genuinely different from THC's. CBD has only weak direct CB1/CB2 affinity; it modulates serotonin (5-HT1A), TRPV1, and PPARγ pathways and is non-intoxicating. The signal that has held up across multiple trials is anxiolysis at moderate-to-high doses: McCartney et al. (Sports Medicine - Open, 2020) found 300-600 mg CBD reduced subjective anxiety in stress-inducing contexts, consistent with earlier work by Bergamaschi et al. (Neuropsychopharmacology, 2011). The 2025 Sahinovic et al. (JFMK) randomized trial of 300 mg acute CBD before a 2-mile time trial reported increased self-reported calm/relaxation and an 8% reduction in mile-1 RPE without performance decrement.

What CBD does not reliably do, in athlete-specific evidence: dramatically reduce delayed-onset muscle soreness, accelerate measured biomarker recovery, or out-perform ice, compression, massage, and NSAIDs as a recovery modality. See CBD and athletes for the full evidence audit.

Recovery and the REM Trade-off

The recovery story has two distinct strands. THC reduces sleep latency at low-to-moderate doses but suppresses REM sleep (Schierenbeck et al., Sleep Medicine Reviews, 2008; Babson et al., Current Psychiatry Reports, 2017). REM is implicated in motor-skill consolidation (Stickgold, Nature, 2005) — meaning chronic nightly THC is a documented trade-off for skill-dependent sports like golf, gymnastics, archery, shooting, and technical climbing. CBD at ≥150 mg has shown modest sleep-continuity improvement in anxiety-driven insomnia (Shannon et al., Permanente Journal, 2019, n=72) — with the well-known caveat that this was an uncontrolled retrospective chart review.

For DOMS, mixed signals: Hatchett et al. (JFMK, 2020), Cochran-Biederman et al. (Sports Medicine - Open, 2021), and Isenmann et al. (Sports Medicine, 2024) report modest reductions in self-reported soreness with limited objective biomarker change. See Recovery and sleep and Pain and inflammation for the deeper dive.

The Marketing-vs-Evidence Gap

The CBD market is large and growing. Grand View Research (2025) estimated the global CBD market at USD 10.68 billion in 2025, projected to USD 30.96 billion by 2033 at a 13.70% compound annual growth rate. (BDS Analytics's earlier $20-billion-by-2024 projection for the U.S. did not materialize.) Most product claims outrun the evidence: a content analysis by Burns et al. (Cannabis and Cannabinoid Research, 2021) of 39 FDA Warning Letters issued 2015-2019 found 97% cited illicit unapproved-new-drug claims for >125 unique health problems, including cancer (87.2%) and inflammation (66.7%). FDA enforcement continued in 2024 (9 letters) and into 2025-2026 under Executive Order 14370 (December 18, 2025).

For athletes specifically, the practical implication is that buying CBD on label claims alone is risky — both for outsized expectations and for THC-contamination AAFs. The third-party-certification path (NSF Certified for Sport, Informed Sport, BSCG) is covered on NSF Certified for Sport and the contamination math on THC contamination risk.

How to Read This Section

The pages that follow are organized by mechanism and outcome rather than by cannabinoid:

• The endocannabinoid system and exercise — the runner's high, anandamide, and why exercise activates the same receptor system that exogenous cannabinoids bind.
• THC and athletic performance — aerobic, anaerobic, strength, bronchodilation, and the negative time-to-exhaustion finding.
• CBD and athletes — pharmacology, anxiolysis, sleep, DOMS, and the marketing audit.
• Recovery and sleep — sleep latency, REM suppression, the motor-skill trade-off, topical CBD.
• Pain and inflammation — PPARγ, TRPV1, adenosine A2A, opioid-sparing.
• Mental health — biphasic anxiety dose-response, competition pressure, post-career mental health.